Lifecore Biomedical, Inc. \de\ (LFCR) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Lifecore Biomedical, Inc. \de\ reported revenue of $128.9M, up 0.5% from $128.3M the year before. Net income was -$38.7M (a -30.0% net margin), or -$1.27 per diluted share. Gross margin was 31.3% and operating margin was -13.4%. Operating activities generated -$206,000 of cash, leaving -$13.6M of free cash flow. At fiscal year end, Lifecore Biomedical, Inc. \de\ held $239.3M in total assets against $191.9M in total liabilities, including $8.3M of cash and equivalents.
Open the full interactive Lifecore Biomedical, Inc. \de\ financials → Quarterly statements, key ratios, valuation history and price charts.
Lifecore Biomedical, Inc. \de\ Key Stats
| Share Price | $6.42 |
|---|---|
| Market Cap | $241.2M |
| Revenue YoY Growth | +0.5% |
| 52-Week Range | $3.66 – $8.82 |
| Shares Outstanding | 37.6 million (basic, 2027 Q2) |
Lifecore Biomedical, Inc. \de\ Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $590.4M | $544.2M | $185.8M | $103.3M | $128.3M | $128.9M |
| Cost of Goods Sold | $515.4M | $462.7M | $135.4M | $75.3M | $86.4M | $88.6M |
| Gross Profit | $75.0M | $81.5M | $50.4M | $28.0M | $41.9M | $40.3M |
| Operating Income | -$38.5M | -$13.5M | -$41.3M | -$21.8M | -$8.8M | -$17.2M |
| Pre-Tax Income | -$51.3M | -$40.5M | -$52.1M | -$63.9M | $9.5M | -$38.7M |
| Income Tax | -$13.1M | -$7.8M | -$5.8M | $308,000 | $183,000 | $43,000 |
| Net Income | -$38.2M | -$32.7M | -$97.4M | -$99.6M | $12.0M | -$38.7M |
| Diluted EPS | -$1.31 | -$1.12 | -$3.31 | -$3.32 | $0.32 | -$1.27 |
Lifecore Biomedical, Inc. \de\ Quarterly Results
| 2025 Q4 | 2026 Q1 | 2026 Q3 | 2027 Q2 | |
|---|---|---|---|---|
| Revenue | $36.4M | $31.1M | $23.2M | $34.2M |
| Net Income | -$1.1M | -$10.0M | -$15.0M | -$6.2M |
| Diluted EPS | -$0.03 | -$0.29 | -$0.43 | -$0.19 |
Lifecore Biomedical, Inc. \de\ Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $360,000 | $1.3M | $1.6M | $19.1M | $8.5M | $8.3M |
| Current Assets | $157.1M | $148.3M | $123.7M | $93.9M | $81.0M | $85.7M |
| Total Assets | $541.3M | $502.9M | $295.2M | $253.5M | $254.0M | $239.3M |
| Current Liabilities | $164.4M | $101.9M | $79.2M | $39.3M | $38.9M | $30.2M |
| Total Long-Term Debt | $112.9M | $164.9M | $98.2M | $84.8M | $101.6M | $130.4M |
| Total Liabilities | $310.3M | $300.1M | $187.2M | $218.5M | $200.1M | $191.9M |
| Shareholders' Equity | $231.0M | $202.8M | $107.9M | -$4.2M | $11.3M | $1.3M |
Lifecore Biomedical, Inc. \de\ Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$17.0M | $15.0M | -$24.4M | -$17.4M | -$217,000 | -$206,000 |
| Cash From Investing | -$23.9M | -$10.9M | $81.8M | -$4.8M | -$17.9M | -$6.4M |
| Cash From Financing | $40.0M | -$3.4M | -$57.0M | $39.7M | $7.5M | $6.4M |
| Free Cash Flow | -$43.7M | -$8.8M | -$50.6M | — | — | -$13.6M |
Figures from Lifecore Biomedical, Inc. \de\'s 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Lifecore Biomedical, Inc. \de\ financials page for every line item.
Lifecore Biomedical, Inc. \de\ Company Profile
| Ticker | LFCR |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Chaska, Minnesota |
| Incorporated in | Delaware |
| Fiscal Year End | May 25 |
| SEC Filer Category | Accelerated filer, smaller reporting company |
| SEC CIK | 0001005286 |
Frequently Asked Questions
What was Lifecore Biomedical, Inc. \de\'s revenue in fiscal 2025?
Lifecore Biomedical, Inc. \de\ (LFCR) reported revenue of $128.9M for fiscal 2025.
What is Lifecore Biomedical, Inc. \de\'s annual revenue history?
Lifecore Biomedical, Inc. \de\'s annual revenue by fiscal year: 2020: $590.4M; 2021: $544.2M; 2022: $185.8M; 2023: $103.3M; 2024: $128.3M; 2025: $128.9M.
What was Lifecore Biomedical, Inc. \de\'s net income in fiscal 2025?
Lifecore Biomedical, Inc. \de\ reported net income of -$38.7M for fiscal 2025.
What was Lifecore Biomedical, Inc. \de\'s earnings per share (EPS) in fiscal 2025?
Lifecore Biomedical, Inc. \de\'s diluted EPS was -$1.27 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Lifecore Biomedical, Inc. \de\ generate in fiscal 2025?
Lifecore Biomedical, Inc. \de\ generated -$13.6M of free cash flow in fiscal 2025.
What was Lifecore Biomedical, Inc. \de\'s revenue last quarter?
In its most recent reported quarter (2027 Q2), Lifecore Biomedical, Inc. \de\ reported revenue of $34.2M.
How much debt does Lifecore Biomedical, Inc. \de\ have?
Lifecore Biomedical, Inc. \de\ reported $130.4M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Lifecore Biomedical, Inc. \de\ are outstanding?
Lifecore Biomedical, Inc. \de\ reported a weighted average of 37.6 million basic shares outstanding in 2027 Q2.
What is Lifecore Biomedical, Inc. \de\'s market cap?
Based on its latest closing price, Lifecore Biomedical, Inc. \de\ (LFCR) has a market capitalization of about $241.2M.
When does Lifecore Biomedical, Inc. \de\'s fiscal year end?
Lifecore Biomedical, Inc. \de\'s fiscal year end, as registered with the SEC, is May 25.
Where is Lifecore Biomedical, Inc. \de\ headquartered?
Lifecore Biomedical, Inc. \de\ lists its business address in Chaska, Minnesota in its SEC filings.